pI: 9.3494 |
Length (AA): 516 |
MW (Da): 57784 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
21 | 515 | 1v59 (A) | 1 | 477 | 36.00 | 0 | 1 | 1.3526 | -0.06 |
23 | 64 | 3p1w (A) | 2 | 43 | 26.00 | 0 | 0.05 | 0.380695 | -0.69 |
23 | 516 | 1dxl (A) | 4 | 470 | 40.00 | 0 | 1 | 1.38466 | -0.2 |
26 | 510 | 3urh (A) | 3 | 462 | 39.00 | 0 | 1 | 1.42632 | -0.54 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | 16 hs Trophozoite, Erthyrocytic stages. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Gametocyte, 22 hs Schizont, Female gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | 4 hs Ring, Male gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Ookinete. | Otto TD |
Otto TD | A comprehensive evaluation of rodent malaria parasite genomes and gene expression. |
Yeoh LM | Comparative transcriptomics of female and male gametocytes in Plasmodium berghei and the evolution of sex in alveolates. |
Ortholog group members (OG5_126968)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G48030 | dihydrolipoyl dehydrogenase 1 |
Arabidopsis thaliana | AT3G17240 | dihydrolipoyl dehydrogenase 2 |
Babesia bovis | BBOV_IV007190 | dihydrolipoamide dehydrogenase, putative |
Brugia malayi | Bm1_26290 | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative |
Candida albicans | CaO19.13546 | similar to S. cerevisiae LPD1 (YFL018C) dihydrolipoamide dehydrogenase component of 3 multi-enzyme complexes of the mitochondria |
Candida albicans | CaO19.6127 | similar to S. cerevisiae LPD1 (YFL018C) dihydrolipoamide dehydrogenase component of 3 multi-enzyme complexes of the mitochondria |
Caenorhabditis elegans | CELE_LLC1.3 | Protein DLD-1, isoform B |
Chlamydia trachomatis | CT_557 | dihydrolipoyl dehydrogenase |
Dictyostelium discoideum | DDB_G0291648 | dihydrolipoamide dehydrogenase |
Drosophila melanogaster | Dmel_CG7430 | CG7430 gene product from transcript CG7430-RA |
Escherichia coli | b0116 | lipoamide dehydrogenase, E3 component is part of three enzyme complexes |
Echinococcus granulosus | EgrG_000870200 | dihydrolipoamide dehydrogenase |
Echinococcus multilocularis | EmuJ_000870200 | dihydrolipoamide dehydrogenase |
Homo sapiens | ENSG00000091140 | dihydrolipoamide dehydrogenase |
Leishmania braziliensis | LbrM.32.3600 | dihydrolipoamide dehydrogenase, putative |
Leishmania donovani | LdBPK_323510.1 | dihydrolipoamide dehydrogenase, putative |
Leishmania infantum | LinJ.32.3510 | dihydrolipoamide dehydrogenase, putative |
Leishmania major | LmjF.32.3310 | dihydrolipoamide dehydrogenase, putative |
Leishmania mexicana | LmxM.31.3310 | dihydrolipoamide dehydrogenase, putative |
Mycobacterium leprae | ML2387 | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE |
Mus musculus | ENSMUSG00000020664 | dihydrolipoamide dehydrogenase |
Mycobacterium tuberculosis | Rv0462 | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras |
Mycobacterium ulcerans | MUL_2214 | dihydrolipoamide dehydrogenase |
Neospora caninum | NCLIV_044200 | hypothetical protein |
Oryza sativa | 4326980 | Os01g0328700 |
Plasmodium berghei | PBANKA_1446900 | dihydrolipoyl dehydrogenase, mitochondrial, putative |
Plasmodium falciparum | PF3D7_1232200 | dihydrolipoyl dehydrogenase, mitochondrial |
Plasmodium knowlesi | PKNH_1451700 | dihydrolipoyl dehydrogenase, mitochondrial, putative |
Plasmodium vivax | PVX_100555 | dihydrolipoyl dehydrogenase, mitochondrial, putative |
Plasmodium yoelii | PY04793 | dihydrolipoamide dehydrogenase |
Saccharomyces cerevisiae | YFL018C | dihydrolipoyl dehydrogenase |
Schistosoma japonicum | Sjp_0205700 | ko:K00382 dihydrolipoamide dehydrogenase [EC1.8.1.4], putative |
Schistosoma mansoni | Smp_046740 | dihydrolipoamide dehydrogenase |
Schmidtea mediterranea | mk4.007520.01 | Dihydrolipoyl dehydrogenase, mitochondrial |
Schmidtea mediterranea | mk4.017144.00 | |
Schmidtea mediterranea | mk4.015096.00 | Dihydrolipoyl dehydrogenase, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.11.18870 | dihydrolipoyl dehydrogenase |
Trypanosoma brucei | Tb927.11.16730 | dihydrolipoyl dehydrogenase |
Trypanosoma congolense | TcIL3000.11.16620 | dihydrolipoyl dehydrogenase |
Trypanosoma cruzi | TcCLB.511025.110 | dihydrolipoyl dehydrogenase, putative |
Trypanosoma cruzi | TcCLB.507089.270 | dihydrolipoyl dehydrogenase, putative |
Toxoplasma gondii | TGME49_206470 | pyruvate dehydrogenase complex subunit PDH-E3II |
Theileria parva | TP03_0227 | dihydrolipoamide dehydrogenase, putative |
Trichomonas vaginalis | TVAG_379130 | mercuric reductase, putative |
Trichomonas vaginalis | TVAG_272760 | glutathione reductase, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0561 | dihydrolipoamide dehydrogenase E3 component |
Wolbachia endosymbiont of Brugia malayi | Wbm0559 | dihydrolipoamide dehydrogenase E3 component |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.8470 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.8470 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.8470 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.01.8470 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b0116 | Escherichia coli | essential | goodall |
CELE_LLC1.3 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_LLC1.3 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_LLC1.3 | Caenorhabditis elegans | slow growth | wormbase |
CELE_LLC1.3 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_1446900 this record | Plasmodium berghei | Slow | plasmo |
TGME49_206470 | Toxoplasma gondii | Probably essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Glutathione reductase | 424 aa | 23.0% | 456 aa | Compounds | References |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 510 aa | 29.0% | 496 aa | Compounds | References |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 510 aa | 28.7% | 495 aa | Compounds | References |
Trypanosoma cruzi | trypanothione reductase, putative | 189 aa | 24.9% | 181 aa | Compounds | References |
Trypanosoma cruzi | trypanothione reductase, putative | 492 aa | 23.0% | 514 aa | Compounds | References |
Leishmania major | trypanothione reductase | 491 aa | 22.7% | 503 aa | Compounds | References |
Rattus norvegicus | Thioredoxin reductase 1, cytoplasmic | 499 aa | 26.9% | 465 aa | Compounds | References |
Crithidia fasciculata | Trypanothione reductase | 491 aa | 23.9% | 506 aa | Compounds | References |
Plasmodium falciparum | glutathione reductase | 500 aa | 26.5% | 525 aa | Compounds | References |